AbCellera Biologics
Stock Forecast, Prediction & Price Target
AbCellera Biologics (ABCL) stock Price Target by analysts
$5
Potential upside: 16.27%
AbCellera Biologics price prediction
What is AbCellera Biologics stock analysts` prediction?
AbCellera Biologics stock forecast: Based on 1 Wall Street analysts` predicted price targets for AbCellera Biologics in the last 3 months, the avarage price target is $5, with a high forecast of $NaN. The average price target represents a 16.27% change from the last price of $4.3.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
AbCellera Biologics stock Price Target by analysts
Full breakdown of analysts given AbCellera Biologics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Gary Nachman BMO Capital | 0% 0/1 | 11 months ago | $5 16.27% upside | $2.74 | StreetInsider | Previous targets (0) |
Scott Schoenhaus KeyBanc | 0% 0/2 | about 1 year ago | $5 16.27% upside | $2.6 | StreetInsider | Previous targets (1) |
Scott Schoenhaus KeyBanc | 0% 0/2 | over 1 year ago | $7 62.79% upside | $3.84 | StreetInsider | Previous targets (1) |
Unknown Leerink Partners | N/A | over 2 years ago | $18 318.60% upside | $9.63 | Benzinga | N/A |
Andrea Tan Goldman Sachs | 0% 0/1 | almost 3 years ago | $30 597.67% upside | $10.13 | TheFly | Previous targets (0) |
Unknown Truist Financial | N/A | almost 3 years ago | $29 574.41% upside | $14.49 | Benzinga | N/A |
Unknown Credit Suisse | N/A | about 3 years ago | $34 690.69% upside | $11.85 | Benzinga | N/A |
AbCellera Biologics Financial Estimates
AbCellera Biologics Revenue Estimates
AbCellera Biologics EBITDA Estimates
AbCellera Biologics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $375.20M N/A | $485.42M 29.37% | $38.02M -92.16% | Avg: $52.34M Low: $36.94M High: $100.96M avg. 37.65% | Avg: $65.75M Low: $49.67M High: $97.92M avg. 25.63% | Avg: $119.28M Low: $90.11M High: $177.62M avg. 81.39% | Avg: $163.27M Low: $123.34M High: $243.13M avg. 36.87% |
Net Income
% change YoY
| $153.46M N/A | $158.51M 3.29% | $-146.39M -192.35% | Avg: $-215.18M Low: $-297.84M High: $-86.74M avg. -46.98% | Avg: $-218.44M Low: $-306.51M High: $-109.88M avg. -1.51% | Avg: $-41.92M Low: $-68.59M High: $-28.60M avg. 80.80% | Avg: $-8.67M Low: $-14.19M High: $-5.91M avg. 79.31% |
EBITDA
% change YoY
| $242.47M N/A | $276.24M 13.92% | $-192.15M -169.56% | Avg: $9.57M Low: $6.75M High: $18.47M avg. 104.98% | Avg: $12.03M Low: $9.08M High: $17.91M avg. 25.63% | Avg: $21.82M Low: $16.48M High: $32.49M avg. 81.39% | Avg: $29.87M Low: $22.56M High: $44.48M avg. 36.87% |
EPS
% change YoY
| $0.56 N/A | $0.56 0% | -$0.51 -191.07% | Avg: -$0.62 Low: -$1.03 High: -$0.3 avg. -20.72% | Avg: -$0.71 Low: -$1.06 High: -$0.38 avg. -15.72% | Avg: -$0.15 Low: -$0.24 High: -$0.1 avg. 79.64% | Avg: -$0.03 Low: -$0.05 High: -$0.02 avg. 79.31% |
Operating Expenses
% change YoY
| $107.78M N/A | $191.92M 78.05% | $275.23M 43.40% | Avg: $27.82M Low: $19.63M High: $53.66M avg. -89.89% | Avg: $34.95M Low: $26.40M High: $52.04M avg. 25.63% | Avg: $63.40M Low: $47.89M High: $94.41M avg. 81.39% | Avg: $86.78M Low: $65.56M High: $129.23M avg. 36.87% |
FAQ
What is AbCellera Biologics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 27.90% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -297.84M, average is -215.18M and high is -86.74M.
What is AbCellera Biologics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 45.38% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $36.94M, average is $52.34M and high is $100.96M.
What is AbCellera Biologics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 30.62% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$1.03, average is -$0.62 and high is $-0.3.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering AbCellera Biologics stock. The most successful analyst is Gary Nachman.